Elizabeth S. Klings, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, New York University School of Medicine
BA, New York University



Dr. Klings is a Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program. She is a national clinical leader in the cardiopulmonary management of patients with sickle cell disease and receives consultations and patients referred for second opinions from throughout the US.

Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. In 2017, she chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the Medical and Research Advisory Committee of the Sickle Cell Disease Association. She is crafting the long-term follow-up cardiopulmonary plan for evaluating sickle cell disease patients who have undergone hematopoietic stem cell transplantation or gene therapy as part of a NIH sponsored committee. She is Co-Chair of the Research Committee within the New England Sickle Cell Consortium.

Member
Boston University
Pulmonary Center


Program Director
Boston University
Center for Excellence in Sickle Cell Disease


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Role of Regional Left Ventricular Strain Patterns in Systemic Sclerosis-related Pulmonary Hypertension
07/01/2023 - 06/30/2026 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
American Heart Association


Cardiac Strain Phenotyping of Systemic Sclerosis-related Pulmonary Hypertension
04/01/2023 - 03/31/2026 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
Scleroderma Foundation


Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 07/30/2024 (PI)
United Therapeutics Corporation


A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 05/29/2024 (PI)
United Therapeutics Corporation


Protocol 21427/BAY0903201: ROAR: Riociguat Users Registry
07/13/2021 - 02/28/2024 (PI)
Bayer HealthCare Pharmaceuticals


Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2023 (Subcontract PI)
The University of Pittsburgh Bayer HealthCare


Biomarkers of Left Ventricular Strain in Systemic Sclerosis-related Pulmonary Hypertension
07/27/2022 - 07/27/2023 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
United Therapeutics Corporation


Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2022 (PI)
Reata Pharmaceuticals, Inc.


Left Ventricular Strain in Systemic Sclerosis-related Pulmonary Hypertension
07/01/2021 - 06/30/2022 (Key Person / Mentor)
PI: Justin K. Lui, MD, MS
NIH/National Heart, Lung, and Blood Institute
1F32HL156614-01

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension
05/30/2014 - 05/31/2022 (PI)
Reata Pharmaceuticals, Inc.


Showing 10 of 35 results. Show All Results

A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
03/21/2025 - 03/20/2028 (PI)
Novo Nordisk

AG348-C-026 A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy
03/03/2025 - 03/02/2028 (PI)
Agios Pharmaceuticals, Inc.

SEG101 (STAND): A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and …
01/23/2020 - 03/01/2028 (PI)
Novartis Pharma Corp


An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study
02/03/2025 - 02/02/2028 (PI)
Novo Nordisk

4202-HEM-301: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
03/24/2021 - 03/23/2027 (PI)
Forma Therapeutics, Inc.


Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
08/01/2022 - 04/30/2026 (Subcontract PI)
PI: Elizabeth S. Klings, MD
University of Maryland NIH NHLBI

1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCDCARRE Trial)
05/01/2020 - 04/30/2026 (Subcontract PI)
PI: Elizabeth S. Klings, MD
University of Pittsburgh NIH NHLBI
4UH3HL143192-02

2 U1EMC27864-08-00; Sickle Cell Treatment Demonstration Program
09/01/2021 - 08/31/2025 (Subcontract PI)
PI: Elizabeth S. Klings, MD
Johns Hopkins University HHS HRSA


ASH Research Collaborative-Data Hub Agreement
09/01/2021 - 06/30/2025 (PI)
American Society of Hematology


Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
05/01/2020 - 07/31/2022 (Subcontract PI)
PI: Elizabeth S. Klings, MD
University of Pittsburgh NIH NHLBI
4UH3HL143192-02


Title


Yr Title Project-Sub Proj Pubs
2013 Protein biomarkers of pulmonary hypertension in sickle cell disease 5R21HL107993-02 3
2012 Protein biomarkers of pulmonary hypertension in sickle cell disease 1R21HL107993-01A1 3
2011 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-15-5116 259
2010 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-14-6816 259
2009 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-13-6167 259
2009 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-05 7
2008 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-12-5241 259
2008 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-04 7
2007 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 2P41RR010888-11-8062 259
2007 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-03 7
Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Walters MC, Eapen M, Liu Y, El Rassi F, Waller EK, Levine JE, Strouse JJ, Antin JH, Parikh SH, Bakshi N, Dampier C, Jaroscak JJ, Bergmann S, Wong T, Kota V, Pace B, Lekakis LJ, Lulla P, Nickel RS, Kasow KA, Popat U, Smith W, Yu L, DiFronzo N, Geller N, Kamani N, Klings ES, Hassell K, Mendizabal A, Sullivan K, Neuberg D, Krishnamurti L. Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. Blood Adv. 2025 Mar 11; 9(5):955-965. PMID: 39471440; PMCID: PMC11907447; DOI: 10.1182/bloodadvances.2024013926;
     
  2. Gillmeyer KR, Rinne ST, Rucci JM, Klings ES, Elwy AR, Wiener RS. Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension. Ann Am Thorac Soc. 2025 Feb 11.View Related Profiles. PMID: 39932507
     
  3. Lui JK, Cozzolino M, Winburn M, Trojanowski MA, Soylemez Wiener R, LaValley MP, Bujor AM, Gopal DM, Klings ES. Clustering regional patterns of left ventricular longitudinal strain in systemic sclerosis-related pulmonary hypertension. Int J Cardiol. 2025 Feb 15; 421:132891.View Related Profiles. PMID: 39662748; PMCID: PMC11747944; DOI: 10.1016/j.ijcard.2024.132891;
     
  4. Katbamna B, Wu L, Rodriguez M, King P, Schilling J, Mahar J, Nair AP, Jneid H, Klings ES, Weinhouse GL, Mazimba S, Simon MA, Strauss M, Krittanawong C. The uses of right heart catheterization in cardio-pulmonary disease: State-of-the-art. Am Heart J Plus. 2025 Jan; 49:100488. PMID: 39760109; PMCID: PMC11699050; DOI: 10.1016/j.ahjo.2024.100488;
     
  5. Alwang AK, Law AC, Klings ES, Cohen RT, Bosch NA. Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes. JAMA Intern Med. 2024 Nov 01; 184(11):1365-1372.View Related Profiles. PMID: 39250114; PMCID: PMC11385329; DOI: 10.1001/jamainternmed.2024.4428;
     
  6. Cohen RT, Burrowes SAB, Williams CJ, Neri CM, Klings ES, Jones KC, Walkey AJ, Drainoni ML. SNAP: Supportive non-invasive ventilation for acute chest syndrome prevention for hospitalized children with sickle cell disease: Perspectives of patients, parents, and the healthcare team. Pediatr Blood Cancer. 2024 Sep; 71(9):e31142.View Related Profiles. PMID: 38896013; PMCID: PMC11394287; DOI: 10.1002/pbc.31142;
     
  7. Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2024 Jun; 38(3):657.View Related Profiles. PMID: 36662449; PMCID: PMC11528702; DOI: 10.1007/s10557-023-07431-6;
     
  8. Johnson SW, Wang RS, Winter MR, Gillmeyer KR, Zeder K, Klings ES, Goldstein RH, Wiener RS, Maron BA. Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response. ERJ Open Res. 2024 May; 10(3).View Related Profiles. PMID: 38770008; PMCID: PMC11103711; DOI: 10.1183/23120541.00959-2023;
     
  9. Siskind SM, Johnson TY, Klings ES, Modzelewski KL. Diabetes Screening Rates and Practices in Patients With Sickle Cell Disease. Diabetes Care. 2024 May 01; 47(5):e42-e43.View Related Profiles. PMID: 38489046; PMCID: PMC11148624; DOI: 10.2337/dc23-2396;
     
  10. Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024 May; 11(5):e345-e357. PMID: 38554715
     
Showing 10 of 97 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 97 publications over 27 distinct years, with a maximum of 10 publications in 2024

YearPublications
19992
20003
20014
20022
20031
20041
20052
20062
20072
20082
20093
20102
20113
20123
20131
20146
20154
20162
20173
20185
20195
20207
20218
20226
20236
202410
20252


BU Researchers Helped Develop the First FDA-Approved Gene Therapies to Treat Sickle Cell Disease

BU Today 12/12/2023

Athletes gearing up for Boston Triathlon on July 24

WCVB 7/15/2022

New Strategies Confront the Critical Need to Improve Sickle Cell Disease Care

HealthCity 4/20/2021

Doctors: Battling virus 'has definitely been challenging'

Lancaster Online 3/3/2021

Reducing Care Fragmentation in Sickle Cell Disease

HealthCity 6/16/2020
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

anemia, sickle cell
endothelium
pulmonary hypertension

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St
Boston MA 02118
Google Map

617.638.8679
Download vCard

Klings's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (345) concept(s)
_
Media Mentions
_
Co-Authors
See all (53) people
_
Similar People
See all (60) people
_
Same Department
Search Department